Grant: Alliance Grants
Université de Sherbrooke
$50,000.00
Development of a Cell-Based High-Throughput Functional Screening Assay To Study Host-Virus (COVID-19) Interaction _x000d_ _x000d_
FY 2020-21
Summary
Despite the needs for prophylactic and therapeutic treatments, no drug or vaccine has yet been approved for the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among the options envisaged to control or prevent the spread of SARS-CoV-2, blocking its cell entry with neutralizing antibodies, peptide blockers or protease inhibitors targeting viral (spike protein) and host membrane proteins (ACE2 and TMPRSS2) may be extremely effective to combat the invading virus. Unfortunately, due to the safety concerns related to viral replication, SARS-CoV-2 is classified as a BSL3 agent and its manipulation requires high-containment laboratories and trained personnel. In response to the current pandemic, the goal of this collaborative research project submitted with the partner Immune Biosolutions, a biotech company focusing on the discovery, engineering and development of humanized chicken antibodies for oncology and infectious diseases, is to develop a safe and accurate lentiviral model of SARS-CoV-2 infection that will allow high-throughput screening and validation of COVID-19 innovative therapeutics in BSL2 laboratories.
To this aim, we propose (1) to incorporate the SARS-CoV-2 spike protein (SARS-CoV-2 S) in lentiviral pseudovirions and implement a robust and reproducible fluorescence detection-based functional assay for high-throughput screening and quantification of antiviral drug efficacy through the monitoring of permissive cell infection by eGFP-positive pseudoviral particles; and (2) to screen lung, gastrointestinal and brain cell types for their susceptibility to pseudovirus infection.
It is anticipated that this lentiviral cell-based functional platform will accelerate the discovery and validation of new solutions to fight against current and future coronavirus infections.
Program
Alliance Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
554154-2020
Name nom
SARRET, Philippe
Department département
Head Office
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of a Cell-Based High-Throughput Functional Screening Assay To Study Host-Virus (COVID-19) Interaction _x000d_
_x000d_
Keyword
NSERC
Application summary
Despite the needs for prophylactic and therapeutic treatments, no drug or vaccine has yet been approved for the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among the options envisaged to control or prevent the spread of SARS-CoV-2, blocking its cell entry with neutralizing antibodies, peptide blockers or protease inhibitors targeting viral (spike protein) and host membrane proteins (ACE2 and TMPRSS2) may be extremely effective to combat the invading virus. Unfortunately, due to the safety concerns related to viral replication, SARS-CoV-2 is classified as a BSL3 agent and its manipulation requires high-containment laboratories and trained personnel. In response to the current pandemic, the goal of this collaborative research project submitted with the partner Immune Biosolutions, a biotech company focusing on the discovery, engineering and development of humanized chicken antibodies for oncology and infectious diseases, is to develop a safe and accurate lentiviral model of SARS-CoV-2 infection that will allow high-throughput screening and validation of COVID-19 innovative therapeutics in BSL2 laboratories.
To this aim, we propose (1) to incorporate the SARS-CoV-2 spike protein (SARS-CoV-2 S) in lentiviral pseudovirions and implement a robust and reproducible fluorescence detection-based functional assay for high-throughput screening and quantification of antiviral drug efficacy through the monitoring of permissive cell infection by eGFP-positive pseudoviral particles; and (2) to screen lung, gastrointestinal and brain cell types for their susceptibility to pseudovirus infection.
It is anticipated that this lentiviral cell-based functional platform will accelerate the discovery and validation of new solutions to fight against current and future coronavirus infections.